Intesa Sanpaolo completes buyback of over 14 million shares

Gian Maria Gros-Pietro Chairman at Intesa Sanpaolo Intesa Sanpaolo
Gian Maria Gros-Pietro Chairman at Intesa Sanpaolo - Intesa Sanpaolo
0Comments

Turin – Milan, 14 July 2025 – Intesa Sanpaolo has executed a buyback program involving the purchase of its own shares for annulment. This program was initially disclosed to the market on 26 May 2025 and commenced on 2 June 2025. The bank reported that from 7 July to 11 July 2025, it purchased a total of 14,374,254 shares. These transactions were carried out on the regulated market Euronext Milan, managed by Borsa Italiana.

The purchases accounted for approximately 0.08% of Intesa Sanpaolo’s share capital. The average purchase price was recorded at 4.9118 euros per share, amounting to a total expenditure of 70,603,522.13 euros.

Morgan Stanley Europe SE acted as the third-party intermediary responsible for executing the program independently and without any involvement from Intesa Sanpaolo Group.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.